COMMUNIQUÉS West-GlobeNewswire

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
03/03/2025
Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment [...]
The Ensign Group Grows in Washington; Adds Its First Operations in Alaska and Oregon
03/03/2025
SAN JUAN CAPISTRANO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
Synergy CHC to Attend 37th Annual ROTH Conference
03/03/2025
WESTBROOK, Maine, March 03, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it will attend the 37 [...]
89bio to Participate in the Leerink Partners Global Healthcare Conference
03/03/2025
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
03/03/2025
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage [...]
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
03/03/2025
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS is the first-ever [...]
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
03/03/2025
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 [...]
Cytokinetics to Participate in March Investor Conferences
03/03/2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: [...]
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
03/03/2025
NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in [...]
Marius Pharmaceuticals Partners with Major Academic Medical Center on Education and Research Efforts for Oral Testosterone
03/03/2025
RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals , a pharmaceutical company dedicated to developing innovative therapies for testosterone deficiency, has partnered with Duke University School of [...]
Instinct Science Launches Standards of Care™: The Future of Veterinary Clinical Decision Support
03/03/2025
PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leader in veterinary software innovation, announces the launch of Standards of Care™ (standards.vet), a next-generation clinical decision support tool [...]
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
03/03/2025
Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI. Efficient operations with operating [...]
Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline
03/03/2025
Press Release Paris, 3 rd March, 2025 Full-year 2024 results 1 : Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven [...]
Résultats 2024 - Progrès dans la mise en œuvre du plan FOCUS-27 soutenue par une efficacité accrue et une discipline financière
03/03/2025
Communiqué de presse Paris, le 3 mars 2025 Résultats 1 de l’exercice 2024 : résilience opérationnelle et forte hausse de la génération de trésorerie avant financement dans un contexte difficile Chiffre d’affaires en [...]
Le schéma thérapeutique à base de DARZALEX® (daratumumab) par voie sous-cutanée de Johnson & Johnson reçoit un avis favorable du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, quelle que soit l’éligibilité à la greffe
03/03/2025
S’il est approuvé, le daratumumab sera le seul anti-CD38 disponible pour tous les types de patients atteints d’un myélome multiple nouvellement diagnostiqué, faisant ainsi du daratumumab un traitement fondamental de [...]
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement
03/03/2025
Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the successful completion of a [...]
Health-ISAC Releases Its 2024 Annual Report
03/03/2025
Insights on Achievements in Strengthening Global Health Sector Resilience ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit industry-led [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
03/03/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 3 March 2025 at 16.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
03/03/2025
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, eradicates B cells in [...]

Pages